ArticleWorld journal of transplantation2026
Clinical predictors of SARS-CoV-2 vaccine immunogenicity in kidney transplant recipients at a rural center.
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney transplant recipients (KTR) have impaired immune responses to vaccination and remain at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite mRNA coronavirus disease 2019 (COVID-19) vaccination. Data from rural and medically underserved transplant populations remain limited.
aimTo evaluate serologic response to a two dose mRNA SARS-CoV-2 vaccination series and identify clinical factors associated with antibody response in KTR.
methodsThis single center retrospective observational study included adult KTR who completed a two dose mRNA COVID-19 vaccination series and had post vaccination anti spike IgG testing performed using stored serum samples. Multivariable logistic regression was used to identify predictors of seroconversion. Among responders, linear regression was used to evaluate factors associated with quantitative antibody titers.
resultsA total of 108 KTR were included, of whom 63 (58.3%) achieved seroconversion. Higher estimated glomerular filtration rate showed independent association with seroconversion, while higher mycophenolic acid dose showed inverse association with response. Black race and basiliximab induction demonstrated association with seroconversion, though estimates were imprecise. Age, sex, body mass index, vaccine type, tacrolimus levels, and comorbidities were not independently associated with response. Among responders, no clinical or demographic variables were significantly associated with antibody titers.
conclusionAfter two dose mRNA vaccination, fewer than two thirds of KTR developed detectable anti spike antibodies. Serologic response was associated with allograft function and antimetabolite exposure, while antibody magnitude was not explained by routine clinical factors in this cohort. These findings provide real world data from a rural transplant population and support consideration of augmented vaccination strategies in KTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.